Navigation Links
China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
Date:8/22/2007

SHANGHAI, China, Aug. 22 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, announced today that it has signed an agreement with Bright Dairy & Food Co., Ltd. ("Bright Dairy") (SSE: 600597) to supply probiotics for Bright Dairy's ice cream products for the next three years.

China-Biotics works as an optimal solution provider for probiotics additives in ice cream products with Bright Dairy. The ice cream packaging will include China-Biotics' registered "Shining Probiotics" trademark. Ice cream sold with probiotics additives will be one of Bright Dairy's hallmark products and have higher margins than other ice creams. This is the first time probiotics are being used as additives in ice cream products in China, allowing consumers to improve their gastrointestinal health through the intake of probiotics as they enjoy the ice cream.

"We are very pleased to establish this partnership with Bright Dairy, one of the top three producers in China's dairy industry," said Mr. Jinan Song, Chief Executive Officer and Chairman of China-Biotics. "This is a significant milestone for us, marking the first time we sell probiotics as food additives; and this contract further validates the demand for probiotics food additives in China. With the increasing affluence and health awareness of Chinese consumers, we believe that the demand for probiotics additives is growing rapidly."

Currently, China-Biotics will supply the additives from its existing facility. In order to meet the demand for probiotics additives, the Company plans to build a new, 150-metric-ton production facility, which will significantly increase its capacity to meet the expected demand for bulk additives. The Company expects to commence production in the new plant during the latter part of the 2008 calendar
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. JT Packard exec resigns after settling copyright disputes
2. Cray signs $250M deal to develop supercomputer
3. Donley resigns as WiCell director
4. WARF signs licensing pact with BD Biosciences
5. TeraMedica signs agreement with ThedaCare
6. CATI signs agreement for food processing technology
7. Doyle signs bill that impacts electronic medical records
8. Doyle signs "self-dealing" bill
9. Electronic signs for municipalities: Las Vegas or lost revenues?
10. NorthStar signs exclusive agreement with Illinois foundation
11. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... advanced cell culture products, announces the availability of BI’s line of human mesenchymal ... Industries, these stem cell differentiation media offer a complete system for multipotency evaluation ...
(Date:7/28/2015)... ... 29, 2015 , ... The new Xsample 530 sample changer for vials can be ... liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) ... immediately catches the eye about Xsample 530 is its removable magazine, which is easily lifted ...
(Date:7/28/2015)... , July 21, 2015 ... announced the addition of the "Analysis of ... to their offering. Globally, flow cytometry ... immuno-phenotyping, cell proliferation, cancer, and stem cells. But ... applications primarily because of demand from underdeveloped nations ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... Majority of Physicians are Most Concerned About Lack of Reimbursement ... from ... Decision Resources, ... leading research and advisory firms for pharmaceutical and,healthcare issues, finds ...
... Wall Street Journal published,an article on October 29th ... Group LLC and featuring quotes from,President and founder ... Use of Transfusions: New Efforts to Recycle Blood ... Risks, is part of the "The Informed Patient",series ...
... 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, today reported that it ... its Phase 2 trial in endometrial,cancer with AEZS-108, ... The decision to enter the second stage of,patient ...
Cached Biology Technology:The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use 2The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... heart attack, the portions of the heart damaged by a ... ways to avoid this scarring, which can harden the walls ... the body and eventually lead to heart failure. But new ... School of Medicine shows that interrupting this process can weaken ...
... 2011, Stephen Boppart from the University of Illinois ... convened by the Optical Society of America (OSA). The ... Advisory Committee for the Congressional Research and Development Caucus. ... and of bioengineering at Illinois, will be the first ...
... Nairobi, 15 November 2011 Farmer trainers should be ... rather than on their successes in implementing farming techniques, shows ... the World Agroforestry Centre (ICRAF). , In the study by ... shrubs, fast-growing leguminous shrubs for feeding dairy cows, in Kenya ...
Cached Biology News:Scarring a necessary evil to prevent further damage after heart attack 2Boppart presents at Congressional briefing 2Teaching skills key to selection of a successful model farmer 2
... Analysis Note: Protein determined by Biuret ... 25 mM Tris-HCl, pH 7.6, 1 mM ... 2 Preparation Unit Definition: One unit ... per minute at pH 9.8 at 37 ...
... Kit measures adenosine triphosphate (ATP) ... a dynamic range. Based on ... measures ATP in bacterial, plant ... concentration range of 10-11 to ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... The RVT405DDA Refrigerated Vapor Trap is ... high boiling solvents such as DMSO ... systems. Its constant temperature refrigeration system ... optimum cryopumping conditions for DMSO, while ...
Biology Products: